C80.2
BillableMalignant neoplasm associated with transplanted organ
Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)
Is C80.2 an HCC code?
Yes. C80.2 maps to Melanoma and Other Skin Cancers under the CMS-HCC V28 risk adjustment model (and Breast, Prostate, and Other Cancers and Tumors under V24).
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for C80.2
For C80.2 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C80.2 during that encounter — not just copy-forwarded from a problem list.
What This Code Means
C80.2 is the ICD-10-CM diagnosis code for malignant neoplasm associated with transplanted organ. Cancer that develops in an organ that was transplanted into a patient from a donor. C80.2 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of ill-defined, other secondary and unspecified sites (c76-c80).
Under the CMS-HCC V28 risk adjustment model, C80.2 maps to Melanoma and Other Skin Cancers (HCC 23) with a community, non-dual, aged base RAF weight of 0.251. Under the older CMS-HCC V24 model, C80.2 maps to Breast, Prostate, and Other Cancers and Tumors (HCC 12) with a community, non-dual, aged base RAF weight of 0.150. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
Document the type of transplanted organ and the cancer type when possible. Because C80.2 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for C80.2 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •Document the type of transplanted organ and the cancer type when possible
- •This code indicates post-transplant malignancy; coordinate with transplant history in medical record
Clinical Significance
Malignant neoplasm associated with transplanted organ captures cancers that develop in or are directly related to organ transplantation, including donor-transmitted malignancies and post-transplant lymphoproliferative disorder (PTLD). Transplant recipients have a 2-4 fold increased cancer risk due to chronic immunosuppression, and these malignancies often behave more aggressively. This diagnosis requires careful coordination between oncology and transplant teams regarding immunosuppression management.
Documentation Requirements
- ✓Documentation that the malignancy is associated with or arose in a transplanted organ
- ✓Type of transplant (kidney, liver, heart, lung, etc.) coded separately with Z94 codes
- ✓Specific cancer type if identifiable (code additionally if possible)
- ✓Current immunosuppression regimen and any modifications made due to the malignancy
- ✓Whether the cancer was donor-transmitted or developed de novo post-transplant
- ✓Duration since transplant to cancer diagnosis
Use Additional Code
- code to identify the specific malignancy
Code First
- complication of transplanted organ (T86.-)